

EUROPEAN CURRICULUM VITAE



PERSONAL INFORMATION

Name	FEDERICA MORANO
Telephone	+39 02/23903842
Fax	+39 02/23902149
E-mail	federica.morano@istitutotumori.mi.it
Nationality	Italian

WORK EXPERIENCE

May 2019 – ongoing :

Medical Oncology Consultant at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

August 2015 – May 2019:

Medical Oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

August 2014 – June 2015:

Honorary Research Fellow under Prof. David Cunningham, GI & Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK

May 2010 – June 2015:

Special Registrat within the Residency Program in Medical Oncology, directed by Prof. Luigi Frati, "Sapienza" University of Rome.

July 2009 - May 2010:

Attendance as Medical Observer at the Oncology Day-Hospital of Policlinico Umberto I, "Sapienza" University of Rome, directed by Prof. Enrico Cortesi

December 2007 - July 2009:

Attendance as a Medical Student at the Oncology Day-Hospital of

EDUCATION AND TRAINING

09/06/2015: Graduation in Medical Oncology Cum Laude "Sapienza" University of Rome

Thesis: "Caratteristiche istopatologiche, fattori prognostici ed outcomes clinici nei pazienti affetti da neoplasie neuroendocrine dell'apparato gastrointestinale: l'esperienza del Royal Marsden Hospital"

Final grade: 70/70 summa cum Laude

28/08/2014: Enrollment to the General Medical Council (GMC), United Kingdom

03/03/2010: Enrollment to "Albo dei Medici - Chirurghi" of Matera

27/07/2009: Graduation in Medicine and Surgery Cum Laude "Sapienza" University of Rome.

Thesis: "Studio clinico monocentrico con Fulvestrant in pazienti in menopausa affette da tumore della mammella in fase avanzata".

Final grade: 110/110 summa cum laude

July 2003: High School Degree

Liceo Scientifico "Enrico Fermi", Policoro (Matera)

Final grade: 100/100

TEACHING ACTIVITIES

25/01/2017: "Impatto clinico nella stadiazione dei tumori gastrointestinali: Quando è necessario eseguire un agoaspirato linfonodale?"

12/12/2017: "Microbi e cancro: amici o nemici ruolo del microbiota nella risposta alla terapia con anticorpi monoclonali nei tumori gastrointestinali avanzati". Piano formazione aziendale, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

14/02/2022- ongoing: Lecturer for the Medical Oncology Residency Program, "Università degli Studi di Milano", Milan

09/06/2023: Master di I livello in Nutrizione e dietetica applicata nel paziente oncologico - A.A. 2022-2023, "Università degli Studi di Milano", Milan

PRIZES and AWARDS

25/10/2018: Premio Marzia Galli Kienle - 4th Position

16/11/2018: Best Oral Abstract Presentation At 20th AIOM National Congress: "Microsatellite Instability (MSI) in Resected Gastric Cancer: Correlation with Clinicopathologic and Molecular Profile. A Translational Analysis of ITACA-S Study"

31/12/2020: Premio Giovani Ricercatori 2019-2020 – area ricerca clinica – Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

22/10/2021: Premio Progetto Carcinoma di Merkel at 23th AIOM National Congress

17/03/2023: "Premio Nadia Catania nell'ambito del tumore del colon retto" at 63rd SIC (Società Italiana di Cancerlogia) National Congress

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES**ENGLISH**

- Reading skills EXCELLENT
- Writing skills EXCELLENT
- Verbal skills EXCELLENT

RELATIONSHIP SKILLS

Good attitude and capacity to work in group
Good capacity of communication

TECHNICAL SKILLS

Good knowledge of Microsoft Office programs (word, excel, power point) and internet

FURTHER INFORMATION

Member of "Associazione Italiana Oncologia Medica" (AIOM)
Member of "European Society of Medical Oncology" (ESMO)
Member of "American Society of Clinical Oncology" (ASCO)

11/2024: Abilitazione Scientifica Nazionale alle funzioni di professore universitario di seconda fascia (Settore Concorsuale 06/D3 – MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA)

2019 – 2023: Member of the Working Group AIOM GIOVANI

2020 – ongoing: Member of the Working Group FICOG – Giovani Oncologi

2023 – ongoing: Council Member AIOM – Regione Lombardia

ATTACHMENTS

PUBLICATIONS

PUBLICATIONS

1. Mezi S, Musio D, Orsi E, de Felice F, Verdinelli I, **Morano F**, Raffetto N, Tombolini V. Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. *Acta Oncol.* 2013 Jan;52(1):187-90. doi: 10.3109/0284186X.2012.689114. Epub 2012 Jun 7.
2. Passaro A, Palazzo A, Trenta P, Mancini ML, **Morano F**, Cortesi E. Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. *Curr Med Chem.* 2012;19(22):3689-700. Review.
3. Iacovelli R, Palazzo A, Mezi S, **Morano F**, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. *Acta Oncol.* 2012 Sep;51(7):873-9. doi: 10.3109/0284186X.2012.705019
4. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. (COLLABORATORS: Cognetti F, Rosso R, Venturini M, De Placido S, Bruzzi P, Pastorino S, Venturini M, Abate A, Pastorino S, Canavese G, Vecchio C, Guenzi M, Lambertini M, Levaggi A, Giraudi S, Accortanzo V, Floris C, Aitini E, Fornari G, Miraglia S, Buonfanti G, Cherchi M, Petrelli F, Vaccaro A, Magnolfi E, Contu A, Labianca R, Parisi A, Basurto C, Cappuzzo F, Merlano M, Russo S, Mansutti M, Poletto E, Nardi M, Grasso D, Fontana A, Isa L, Comandè M, Cavanna L, Iacobelli S, Milani S, Mustacchi G, Venturini S, Scinto A, Sarobba M, Pugliese P, Bernardo A, Pavese I, Cocco M, Massidda B, Ionta MT, Nuzzo A, Laudadio L, Chiantera V, Dottori R, Barduagni M, Castiglione F, Ciardiello F, Tinessa V, Ficarella A, Moschetti L, Vallini I, Giardina G, Silva R, Montedoro M, Seles E, **Morano F**, Cruciani G, Adamo V, Pancotti A, Palmisani V, Ruggeri A, Cammilluzzi E, Carrozza F, D'Aprile M, Brunetti M, Gallotti P, Chiesa E, Testore F, D'Arco A, Ferro A, Jirillo A, Pezzoli M, Scambia G, Iacono C, Masullo P, Tomasello G, Gandini G, Zoboli A, Bottero C, Cazzaniga M, Genua G, Palazzo S, D'Amico M, Perrone D). Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. *Lancet.* 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.
5. Grande R, Natoli C, Ciancola F, Gemma D, Pellegrino A, Pavese I, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, **Morano F**, Sergi D, Signorelli C, Ruggeri EM, Zampa G, Russano M, Gamucci T. Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. *PLoS One.* 2016 Jul 21;11(7):e0157751. doi: 10.1371/journal.pone.0157751.
6. Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, **Morano F**, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F. MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer. *Cancer Discov.* 2016 Sep;6(9):963-71. doi: 10.1158/2159-8290.CD-16-0297.
7. Pietrantonio F, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, Busico A, Settanni G, Berenato R, Caporale M, **Morano F**, Bossi I, Pellegrinelli A, Di Bartolomeo M, de Braud F, Baratti D,

- Bowne WB, Kusamura S, Deraco M. Towards the molecular dissection of peritoneal pseudomyxoma. *Ann Oncol*. 2016 Nov;27(11):2097-2103.
8. Pietrantonio F, Caporale M, **Morano F**, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *Int J Cancer*. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408.
 9. Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, **Morano F**, Picciani B, Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A, de Braud F. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. *Clin Cancer Res*. 2016 Oct 25. doi: 10.1158/1078-0432.CCR-16-1863
 10. Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, **Morano F**, Rossini D, Battaglin F, Baretta M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, Loupakakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C. Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. *Ann Oncol*. 2017 Mar 1;28(3):555-561. doi: 10.1093/annonc/mdw627.
 11. Pietrantonio F, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, **Morano F**, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, de Braud F, Mazzaferro V. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. *Clin Colorectal Cancer*. 2016 Oct 6. pii: S1533-0028(16)30201-8. doi: 10.1016/j.clcc.2016.09.007.
 12. Scialfani F, **Morano F**, Cunningham D, Baratelli C, Kalaitzaki E, Watkins D, Starling N, Chau I, Rao S. Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. *Oncologist*. 2017 Apr;22(4):402-408. doi: 10.1634/theoncologist.2016-0241. Epub 2017 Feb 16.
 13. Scialfani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, **Morano F**, Baratelli C, Kalaitzaki E, Rasheed S, Watkins D, Starling N, Wotherspoon A, Chau I. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. *Oncologist*. 2017 May 5. pii: theoncologist.2016-0396. doi: 10.1634/theoncologist.2016-0396. [Epub ahead of print]
 14. Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, **Morano F**, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. *Br J Cancer*. 2017 Jul 25;117(3):347-352. doi: 10.1038/bjc.2017.196. Epub 2017 Jun 27.
 15. Raspagliesi F, Bogani G, Ditto A, Martinelli F, Chiappa V, Borghi C, Scaffa C, **Morano F**, Maltese G, Lorusso D. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers. *Ann Surg Oncol*. 2017 Oct;24(11):3396-3405. doi: 10.1245/s10434-017-6030-0. Epub 2017 Aug 9.

16. Berenato R, **Morano F**, Pietrantonio F, Cotsoglou C, Caporale M, Infante G, Pellegrinelli A, Alessi A, Battiston C, Coppa J, Padovano B, Mennitto A, Niger M, Fucà G, Lazzati S, Greco G, Delconte G, de Braud F, Mazzaferro V, Di Bartolomeo M. Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. *Oncology*. 2017 Sep 8. doi: 10.1159/000479154. [Epub ahead of print]
17. Cremolini C, **Morano F**, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. *Ann Oncol*. 2017 Sep 25. doi: 10.1093/annonc/mdx546. [Epub ahead of print]
18. Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, **Morano F**, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. *Nature*. 2017 Nov 29. doi: 10.1038/nature24673. [Epub ahead of print]
19. Nichetti F, **Morano F**, Fabbri A, de Braud F, Di Bartolomeo M. Bilateral parotid gland metastases from gastric signet-ring cell carcinoma. *Tumori*. 2017 Nov 22:0. doi: 10.5301/tj.5000690. [Epub ahead of print]
20. Pietrantonio F, Fucà G, **Morano F**, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, De Braud FG, Giordano S, Cremolini C, Di Bartolomeo M. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study. *Clin Cancer Res*. 2017 Dec 5. pii: clincanres.2781.2017. doi: 10.1158/1078-0432.CCR-17-2781. [Epub ahead of print]
21. Cremolini C, Pietrantonio F, Tomasello G, Dadduzio V, Moretto R, **Morano F**, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Ziapir S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. *ESMO Open*. 2017 Aug 10;2(3):e000241. doi: 10.1136/esmoopen-2017-000241. eCollection 2017.
22. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, **Morano F**, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. *J Natl Cancer Inst*. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.
23. Battaglin F, Schirripa M, Buggin F, Pietrantonio F, **Morano F**, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, Scartozzi M, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. *BMC Cancer*. 2018 Jan 25;18(1):98. doi: 10.1186/s12885-018-4001-x.

24. Cremolini C, Milione M, Marmorino F, **Morano F**, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. *Br J Cancer*. 2018 Mar 13. doi: 10.1038/s41416-018-0015-z. [Epub ahead of print]
25. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, **Morano F**, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa S, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. *Ann Oncol*. 2018 Mar 10. doi: 10.1093/annonc/mdy090. [Epub ahead of print]
26. Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, **Morano F**, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. *Target Oncol*. 2018 Mar 27. doi: 10.1007/s11523-018-0562-5. [Epub ahead of print]
27. **Morano F**, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. *Ann Oncol*. 2018 May 31. doi: 10.1093/annonc/mdy197. [Epub ahead of print]
28. Kühnl A, Cunningham D, Hutka M, Peckitt C, Rozati H, **Morano F**, Chong I, Gillbanks A, Wotherspoon A, Harris M, Murray T, Chau I. Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. *BMC Hematol*. 2018 Aug 14;18:19. doi: 10.1186/s12878-018-0109-0. eCollection 2018
29. Pietrantonio F, Barretta F, Fanotto V, Park SH, **Morano F**, Fucà G, Niger M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G. Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. *Oncology*. 2018 Aug 21;1-9. doi: 10.1159/000491753. [Epub ahead of print]
30. **Morano F**, Sclafani F. Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. *Crit Rev Oncol Hematol*. 2018 Nov;131:53-65. doi: 10.1016/j.critrevonc.2018.08.006. Epub 2018 Aug 27.
31. Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, **Morano F**, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V. Perioperative bevacizumab-based triplet chemotherapy in patients with potentially resectable colorectal cancer liver metastases. *Clin Colorectal Cancer*. 2018 Nov 24. pii: S1533-0028(18)30212-3

32. Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari M A, Di Bartolomeo M, **Morano F**, Raimondi A, Fuca` G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Carlo Barone, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA methyltransferase. *European Journal of Cancer* 107 (2019) 164e174
33. Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, **Morano F**, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F. Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Sci Rep.* 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3.
34. Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, **Morano F**, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F. Benefit from anti-EGFRs in *RAS* and *BRAF* wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. *ESMO Open* 2019;4:e000489. doi:10.1136/esmoopen-2019-000489
35. Moretto R, **Morano F**, Ongaro E, Rossini D, Pietrantonio F, Casagrande M, Antoniotti C, Corallo S, Marmorino F, Cortiula F, Nichetti F, Borelli B, Zucchelli G, Boccaccino A, Masi G, De Braud F, Falcone A, Cremolini C. Lack of benefit from anti-EGFR treatment in *RAS* and *BRAF* wildtype metastatic colorectal cancer with mucinous histology or mucinous component. *Clinical Colorectal Cancer* (2019), doi: <https://doi.org/10.1016/j.clcc.2019.02.007>.
36. Di Bartolomeo M, Monica Niger M, **Morano F**, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassinetti GL, Tassinari D, Giulian F, Cinieri S, Maiello E, Verusio C, Sergio Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Soto Parra H, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. *BMC Cancer* (2019) 19:283 <https://doi.org/10.1186/s12885-019-5498-3>
37. Raimondi A, Corallo S, Niger M, Antista M, Randon G, **Morano F**, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F. Metronomic capecitabine plus cyclophosphamide regimen in unresectable or relapsed Pseudomyxoma Peritonei. *Clinical Colorectal Cancer* (2019). Doi: <https://doi.org/10.1016/j.clcc.2019.03.002>
38. Miceli R, An J, Di Bartolomeo M, **Morano F**, Kim ST, Park SH, Choi MG, Lee JH, Raimondi A, Fucà G, Sohn TS, Bae JM, Kim S, Lim DH, Kang WK, Kim KM, Pietrantonio F, Lee J. Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. *Oncology* (2019) May 2:1-6. doi: 10.1159/000499628. [Epub ahead of print]
39. Pietrantonio F, **Morano F**, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smirardo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F. Maintenance

Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncol.* 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

40. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, **Morano F**, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M. A validated prognostic classifier for ^{V600E}BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. *Eur J Cancer* 2019 Sep; 118:121-130. doi: 10.1016/j.ejca.2019.06.008
41. Salati M, Orsi G, Smyth E, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, **Morano F**, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S. Gastric cancer: Translating novel concepts into clinical practice. *Cancer Treat Rev.* 2019 Aug 14;79:101889. doi: 10.1016/j.ctrv.2019.101889. [Epub ahead of print]
42. Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, **Morano F**, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M. CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. *Br J Cancer.* 2019 Sep 2. doi: 10.1038/s41416-019-0560-0. [Epub ahead of print]
43. Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, **Morano F**, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. *J Clin Oncol.* 2019 Sep 12;JCO1901124. doi: 10.1200/JCO.19.01124. [Epub ahead of print]
44. **Morano F**, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. *J Clin Oncol.* 2019 Sep 20;JCO1901254. doi: 10.1200/JCO.19.01254. [Epub ahead of print]
45. Corso S, Isella C, Bellomo SE, Apicella M, Durando S, Migliore C, Ughetto S, D'Errico L, Menegon S, Moya-Rull D, Cargnelutti M, Capeloa T, Conticelli D, Giordano J, Venesio T, Balsamo A, Marchiò C, Degiuli M, Reddavid R, Fumagalli Romario U, de Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Pietrantonio F, **Morano F**, Siena S, Sartore-Bianchi A, Bencivenga M, Mengardo V, Rosati R, Marrelli D, Morgagni P, Rausei S, Pallabazzer G, De Simone M, Ribero D, Marsoni S, Sottile A, Medico E, Cassoni P, Sapino A, Pectasides E, Thorner AR, Nag A, Drinan SD, Wollison BM, Bass AJ, Giordano S. A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. *Cancer Res.* 2019 Oct 4. pii: canres.1166.2019. doi: 10.1158/0008-5472.CAN-19-1166. [Epub ahead of print]
46. Crisafulli G, Mussolin B, Cassingena A, Montone M, Bartolini A, Barault L, Martinetti A, **Morano F**, Pietrantonio F, Sartore-Bianchi A, Siena S, Di Nicolantonio F, Marsoni S, Bardelli A, Siravegna G.

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patient. ESMO Open 2019;4:e000572. doi: 10.1136/esmoopen-2019-000572

47. Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, **Morano F**, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, Randon G, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di Bartolomeo M and de Braud F. Capecitabine and temozolomide versus FOLFIRI in *RAS* mutated, *MGMT* methylated metastatic colorectal cancer. Clin Cancer Res November 18 2019 DOI: 10.1158/1078-0432.CCR-19-3024
48. Di Bartolomeo M, **Morano F**, Raimondi A, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, Randon G, Pagani F, Martinetti A, Fucà G, Pietrantonio F; ITACA-S study group. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Oncologist. 2019 Nov 25. pii: theoncologist.2019-0471. doi: 10.1634/theoncologist.2019-0471. [Epub ahead of print]
49. Giannini R, Zucchelli G, Giordano M, Ugolini C, Moretto R, Ambryszewska K, Leonardi M, Sensi E, **Morano F**, Pietrantonio F, Cremolini C, Falcone A, Fontanini G. Immune Profiling of Deficient Mismatch Repair Colorectal Cancer (dMMR CRC) Tumor Microenvironment Reveals Different Levels of Immune System Activation. J Mol Diagn 2020 Mar 12[Online ahead of print].doi: 10.1016/j.jmoldx.2020.02.008
50. Corallo S, Fucà G, **Morano F**, Salati M, Spallanzani A, Gloghini A, Volpi CC, Trupia DV, Lobefaro R, Guarini V, Milione M, Cattaneo L, Antista M, Prisciandaro M, Raimondi A, Sposito C, Mazzaferro V, de Braud F, Pietrantonio F, Di Bartolomeo M. Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. Oncologist 2020 Apr 9. doi: 10.1634/theoncologist.2020-0037.
51. Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, **Morano F**, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist 2020 May 5. doi: 10.1634/theoncologist.2020-0014.
52. Fucà G, Guarini V, Antoniotti C, **Morano F**, Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L, Sartore-Bianchi A, Borelli B, Tampellini M, Bustreo S, Claravazza M, Boccaccino A, Murialdo R, Zaniboni A, Tomasello G, Loupakis F, Adamo V, Tonini G, Cortesi E, de Braud F, Cremolini C, Pietrantonio F. The Pan-Immune-Inflammation Value Is a New Prognostic Biomarker in Metastatic Colorectal Cancer: Results From a Pooled-Analysis of the Valentino and TRIBE First-Line Trials. Br J Cancer 2020 May 19. doi: 10.1038/s41416-020-0894-7. Online ahead of print.
53. Pietrantonio F, **Morano F**, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clin Colorectal Cancer. 2020 May 23;S1533-0028(20)30077-3. doi: 10.1016/j.clcc.2020.05.004.

54. Moretto R, Corallo S, Belfiore A, Rossini D, Boccaccino A, Lonardi S, Centonze G, **Morano F**, Germani MM, Loupakakis F, Morelli L, Urbani L, Brich S, Marmorino F, Prisciandaro M, Aprile G, Fassan M, Cillo U, Cattaneo L, Fontanini G, De Braud F, Falcone A, Milione M, Pietrantonio F, Cremolini C. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. *Eur J Cancer*. 2020 Jun 15;135:78-88. doi: 10.1016/j.ejca.2020.04.045. Online ahead of print.
55. Raimondi A, Di Maio M, **Morano F**, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Sartore-Bianchi A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Adamo V, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Bergamo F, Niger M, Antista M, Peverelli G, de Braud F, Di Bartolomeo M, Pietrantonio F. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. *Eur J Cancer* 2020 Aug;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Epub 2020 Jul 2.
56. Antoniotti C, Borelli B, Rossini D, Pietrantonio F, **Morano F**, Salvatore L, Lonardi S, Marmorino F, Tamberi S, Corallo S, Tortora G, Bergamo F, Brunella DS, Boccaccino A, Grassi E, Racca P, Tamburini E, Aprile G, Moretto R, Boni L, Falcone A, Cremolini C. Atezotribe: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. *BMC Cancer* . 2020 Jul 22;20(1):683. doi: 10.1186/s12885-020-07169-6.
57. Manca P, Corallo S, Randon G, Lonardi S, Cremolini C, Rimassa L, Bergamo F, Antoniotti C, Smirardo V, Zaniboni A, Murialdo R, Tampellini M, Tomasello G, Clavarezza M, Racca P, Antista M, Raimondi A, Prisciandaro M, Pagani F, Palermo F, Greco FG, Vaiani M, Di Bartolomeo M, de Braud F, Calareso G, **Morano F**, Pietrantonio F. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. *Eur J Cancer*. 2020 Dec 12;144:31-40. doi: 10.1016/j.ejca.2020.11.017. Online ahead of print.
58. Pietrantonio F, Fucà G, Rossini D, Schmoll HJ, Bendell JC, **Morano F**, Antoniotti C, Corallo S, Borelli B, Raimondi A, Marmorino F, Niger M, Boccaccino A, Masi G, Lonardi S, Boni L, de Braud F, Di Bartolomeo M, Falcone A, Cremolini C. FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer patients: a propensity score-based analysis. *Oncologist*. 2020 Dec 18. doi: 10.1002/onco.13642. Online ahead of print.
59. Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, Randon G, de Braud F, Di Bartolomeo M, Pietrantonio F, **Morano F**. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. *Support Care Cancer* 2021 Jan 3. doi: 10.1007/s00520-020-05972-2. Online ahead of print.
60. Corso S, Pietrantonio F, Apicella M, Migliore C, Conticelli D, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Ughetto S, Degiuli M, Reddavid R, Fumagalli Romario U, de Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molino S, de Manzoni G, Bencivenga M, Siena S, Sartore-Bianchi A, **Morano F**, Corallo S, Prisciandaro M, Di Bartolomeo M, Glohini A, Marsoni S, Sottile A, Sapino A, Marchiò C, Dahle-Smith A, Miedzybrodzka Z, Lee J, Ali SM, Ross JS, Alexander BM, Miller VA, Petty R, Schrock AB, Giordano S. Optimized EGFR blockade strategies in EGFR addicted gastroesophageal

adenocarcinomas. Clin Cancer Res.2021 Feb 4;clincanres.0121.2020. doi: 10.1158/1078-0432.CCR-20-0121. Online ahead of print.

61. Manca P, Corallo S, Busico A, Lonardi S, Corti F, Antoniotti C, Procaccio L, Clavarezza M, Smioldo V, Tomasello G, Murialdo R, Sartore-Bianchi A, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Palermo F, Perrone F, Tamborini E, Prisciandaro M, Raimondi A, Di Bartolomeo M, **Morano F**, Pietrantonio F. The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer. Clin Cancer Res. 2021 Feb 5;clincanres.4699.2020. doi: 10.1158/1078-0432.CCR-20-4699. Online ahead of print.
62. Fassan M, Milione M, Maddalena G, Cremolini C, Schirripa M, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Bergamo F, Volante M, Boccaccino A, **Morano F**, Cortiula F, De Maglio G, Rimassa L, Smioldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Salmaso R, Centonze G, Biason P, Borga C, Lonardi S, Zagonel V, Dei Tos AP, Di Maio M, Loupakakis F. Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. Eur J Cancer. 2021 Mar;146:145-154. doi: 10.1016/j.ejca.2021.01.016. Epub 2021 Feb 16.
63. Borelli B, Fontana E, Giordano M, Antoniotti C, Lonardi S, Bergamo F, Pietrantonio F, **Morano F**, Tamburini E, Boccaccino A, Santini D, Zucchelli G, Pella N, Maiello E, Passardi A, Zaniboni A, Ugolini C, Fontanini G, Falcone A, Nyamundanda G, Sadanandam A, Cremolini C. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. ESMO Open. 2021 Mar 3;6(2):100073. doi: 10.1016/j.esmoop.2021.100073. Online ahead of print.
64. Ughetto S, Migliore C, Pietrantonio F, Apicella M, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Rizzolio S, Capelôa T, Ribisi S, Degiuli M, Reddavid R, Rapa I, Fumagalli U, De Pascale S, Ribero D, Baronchelli C, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Manenti S, Bencivenga M, Sacco M, Castelli C, Siena S, Sartore-Bianchi A, Tosi F, **Morano F**, Raimondi A, Prisciandaro M, Gloghini A, Marsoni S, Sottile A, Sarotto I, Sapino A, Marchiò C, Cassoni P, Guarrera S, Corso S, Giordano S. Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer. 2021 Mar 23. doi: 10.1007/s10120-021-01165-w. Online ahead of print. PMID: 33755862
65. Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, **Morano F**, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, Curigliano G, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, Pietrantonio F. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer . 2021 Apr;9(4):e002501. doi: 10.1136/jitc-2021-002501.
66. Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A, de Braud F, **Morano F**, Cremolini C, Pietrantonio F. EGFR Amplification in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2021 Apr 7:djab069. doi: 10.1093/jnci/djab069. Online ahead of print. PMID: 33825902
67. Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, Borelli B, Brambilla M, Prete AA, Quarà V, Antista M, Fassan M, **Morano F**, Spallanzani A, Ambrosini M, Curigliano G, de Braud F, Zagonel V, Fucà G, Pietrantonio F. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021 Jun;150:155-167. doi: 10.1016/j.ejca.2021.03.043. Epub 2021 Apr 24.

68. Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, Ciardiello D, Terminiello M, Borrelli C, Vitiello PP, De Braud F, **Morano F**, Avallone A, Normanno N, Nappi A, Maiello E, Latiano T, Falcone A, Cremolini C, Rossini D, Santabarbara G, Pinto C, Santini D, Cardone C, Zanaletti N, Di Liello A, Renato D, Esposito L, Marrone F, Ciardiello F. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. *JAMA Oncol.* 2021 Aug 12. doi: 10.1001/jamaoncol.2021.2915. Online ahead of print.
69. Raimondi A, Fucà G, Leone AG, Lonardi S, Antoniotti C, Smiroldo V, Amatu A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, Corallo S, **Morano F**, Di Bartolomeo M, Di Maio M, Pietrantonio F. Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. *ESMO Open.* 2021 Aug 17;6(5):100246. doi: 10.1016/j.esmoop.2021.100246. Online ahead of print.
70. Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, **Morano F**, Fucà G, Overman M, Miceli R. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. *J Immunother Cancer.* 2021 Aug;9(8):e003370. doi: 10.1136/jitc-2021-003370.
71. Lonardi S, Prete AA, **Morano F**, Messina M, Formica V, Corsi DC, Orciuolo C, Frassinetti GL, Zampino MG, Casagrande M, Masi G, Ronzoni M, Scartozzi M, Buonadonna A, Mosconi S, Ratti M, Sartore-Bianchi A, Tamburini E, Prisciandaro M, Bergamo F, Spada M, Corallo S, Vettore V, Loupakis F, Fassan M, Del Bianco P, Zagonel V, Pietrantonio F. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. *J Immunother Cancer.* 2021 Nov;9(11):e002996. doi: 10.1136/jitc-2021-002996.
72. Manca P, Corallo S, Lonardi S, Fucà G, Busico A, Leone AG, Corti F, Antoniotti C, Procaccio L, Smiroldo V, Ratti M, Murialdo R, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Prisciandaro M, Ambrosini M, Raimondi A, **Morano F**, Pietrantonio F. Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. *Br J Cancer.* 2021 Nov 22. doi: 10.1038/s41416-021-01591-8. Online ahead of print.
73. Prisciandaro M, Antista M, Raimondi A, Corti F, **Morano F**, Centonze G, Sabella G, Mangogna A, Randon G, Pagani F, Prinzi N, Niger M, Corallo S, Castiglioni di Caronno E, Massafra M, Bartolomeo MD, de Braud F, Milione M, Pusceddu S. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. *Front Oncol* ,2022 Feb 4;12:780716. doi: 10.3389/fonc.2022.780716. eCollection 2022
74. Fucà G, Raimondi A, Prisciandaro M, Lonardi S, Cremolini C, Ratti M, Clavarezza M, Murialdo R, Sartore-Bianchi A, Smiroldo V, Berenato R, Racca R, Bergamo F, Corallo S, Di Bartolomeo M, de Braud F, **Morano F**, Pietrantonio F. Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. *The Oncologist*, Volume 27, Issue 1, January 2022, Pages e29–e36, <https://doi.org/10.1093/oncolo/oyab012>

75. **Morano F**, Raimondi A, Pagani F, Lonardi S, Salvatore L, Cremolini C, Murgioni S, Randon G, Palermo F, Antonuzzo L, Pella N, Racca P, Prisciandaro M, Niger M, Corti F, Bergamo F, Zaniboni A, Ratti M, Palazzo M, Cagnazzo C, Calegari MA, Marmorino F, Capone I, Conca E, Busico A, Brich S, Tamborini E, Perrone F, Di Maio M, Milione M, Di Bartolomeo M, de Braud F, Pietrantonio F. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O 6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. *J Clin Oncol* 2022 Mar 8;JCO2102583. doi: 10.1200/JCO.21.02583. Online ahead of print.
76. Maron SB, Moya S, **Morano F**, Emmett MJ, Chou JF, Sabwa S, Walch H, Peterson B, Schrock AB, Zhang L, Janjigian YY, Chalasani S, Ku GY, Disel U, Enzinger P, Uboha N, Kato S, Yoshino T, Shitara K, Nakamura Y, Saeed A, Kasi P, Chao J, Lee J, Capanu M, Wainberg Z, Petty R, Pietrantonio F, Klempner SJ, Catenacci DVT. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. *J Clin Oncol*. 2022 Mar 29;JCO2102453. doi: 10.1200/JCO.21.02453. Online ahead of print.
77. Crisafulli G, Sartore-Bianchi A, Lazzari L, Pietrantonio F, Amatu A, Macagno M, Barault L, Cassingena A, Bartolini A, Luraghi P, Mauri G, Battuello P, Personeni N, Zampino MG, Pessei V, Vitiello PP, Tosi F, Idotta L, **Morano F**, Valtorta E, Bonoldi E, Germano G, Di Nicolantonio F, Marsoni S, Siena S, Bardelli A. Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. *Cancer Discov* . 2022 May 6;candisc.1434.2021. doi: 10.1158/2159-8290.CD-21-1434. Online ahead of print.
78. Niger M, Nichetti F, Casadei-Gardini A, **Morano F**, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hülle J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruner G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. *Mol Oncol*. 2022 May 27. doi: 10.1002/1878-0261.13256. Online ahead of print.
79. Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, **Morano F**, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopoulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet Oncol* .2022 May 27;S1470-2045(22)00274-1. doi: 10.1016/S1470-2045(22)00274-1. Online ahead of print.
80. Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, **Morano F**, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. *J Clin Oncol* .2022 Jun 6;JCO2200839. doi: 10.1200/JCO.22.00839. Online ahead of print.
81. Raimondi A, Randon G, Prisciandaro M, Pagani F, Lonardi S, Antoniotti C, Bozzarelli S, Sartore-Bianchi A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M,

- Petrelli F, Antonuzzo L, Giordano M, Rossi A, Di Bartolomeo M, Di Maio M, Pietrantonio F, **Morano F**. Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: overall and sex-specific outcomes in the Valentino trial. *Int J Cancer* .2022 Jun 9. doi: 10.1002/ijc.34156. Online ahead of print.
- 82.Niger M, Nichetti F, Casadei-Gardini A, Rizzato MD, Pircher C, Bini M, Franza A, Rimini M, Burgio V, Sposetti C, Fornaro L, Rapposelli IG, D'Amico FE, Aprile G, Vivaldi C, Frassinetti GL, Milione M, Leoncini G, Cappetta A, Vasile E, Fassan M, **Morano F**, Perrone F, Tamborini E, Pruneri G, Lonardi S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. Platinum sensitivity in patients with IDH1/2 mutated versus wild-type intrahepatic cholangiocarcinoma: a propensity score-based study. *Int J Cancer*.2022 Jun 20. doi: 10.1002/ijc.34182. Online ahead of print.
- 83.Baratti D, Kusamura S, Guaglio M, Milione M, Pietrantonio F, Cavalleri T, **Morano F**, Deraco M. Relapse of Pseudomyxoma Peritonei After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Pattern of Failure, Clinical Management and Outcomes. *Ann Surg Oncol*. 2023 Jan;30(1):404-414.doi: 10.1245/s10434-022-12367-6. Epub 2022 Sep 12.
- 84.Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. (COLLABORATORS: Venturini M, Abate A, Pastorino S, Canavese G, Vecchio C, Guenzi M, Lambertini M, Levaggi A, Giraudi S, Accortanzo V, Floris C A, Aitini E, Fornari G, Miraglia S, Buonfanti G, Cherchi MC, Petrelli F, Vaccaro A, Magnolfi E, Contu A, Labianca R, Parisi A, C Basurto C, Cappuzzo F, Merlano M, Russo S, Mansutti M, Poletto E, Nardi M, Grasso D, Fontanam A, Isa L, Comandè M, Cavanna L, Iacobelli S, Milani S, Mustacchi G, Venturini S, Scinto A F, Sarobba M G, Pugliese P, Bernardo A, Pavese I, Cocco M, Massidda B, Ionta M T, Nuzzo A, Laudadio L, Chiantera V, Dottori R, Barduagni M, Castiglione F, Ciardiello F, Tinessa V, Ficorella A, Moscetti L, Vallini I, Giardina G, Silva R, Montedoro, E Seles M, **Morano F**, Cruciani G, Adamo V, Pancotti A, Palmisani V, Ruggeri A, Cammilluzzi E, Carrozza F, D'Aprile M, Brunetti M, Gallotti P, Chiesa E, Testore F, D'Arco A, Ferro A, Jirillo A, Pezzoli M, Scambia G, Iacono C, Masullo P, Tomasello G, Gandini G, Zoboli A, Bottero C, Cazzaniga M, Genua G, Palazzo S, D'Amico M, Perrone D). Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. *Lancet Oncol*. 2022 Dec;23(12):1571-1582.doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10.
- 85.Pietrantonio F, Manca P, Bellomo SE, Corso S, Raimondi A, Berrino E, **Morano F**, Migliore C, Niger M, Castagnoli L, Pupa SM, Marchiò C, Di Bartolomeo M, Restuccia E, Lambertini C, Tabernero J, Giordano S. HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial. *Clin Cancer Res*. 2022 Nov 22;CCR-22-2533. doi: 10.1158/1078-0432.CCR-22-2533. Online ahead of print.
- 86.Castagnoli L, Corso S, Franceschini A, Raimondi A, Bellomo SE, Dugo M, **Morano F**, Prisciandaro M, Bric S, Belfiore A, Vingiani A, Di Bartolomeo M, Pruneri G, Tagliabue E, Giordano S, Pietrantonio F, Pupa SM. Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. *Cell Oncol (Dordr)*. 2023 Feb 8. doi: 10.1007/s13402-023-00769-x. Online ahead of print.PMID: 36753044
- 87.Prete AA, Manca P, Messina M, Formica V, Frassinetti GL, Zampino MG, Corsi DC, Orciuolo C, Prisciandaro M, Bergamo F, Angerilli V, Scartozzi M, Casagrande M, Masi G, Ronzoni M, **Morano F**, Vettore V, Salmaso R, Rasola C, Maddalena G, Del Bianco P, Milione M, Cremolini C, Fassan M,

- Pietrantonio F, Lonardi S. Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. *Eur J Cancer*. 2023 Jan 9;182:87-97. doi: 10.1016/j.ejca.2022.12.025. Online ahead of print.PMID: 36753836
- 88.Leone AG, Trapani D, Schabath MB, Safer JD, Scout NFN, Lambertini M, Berardi R, Marsoni S, Perrone F, Cinieri S, Miceli R, **Morano F**, Pietrantonio F. Cancer in Transgender and Gender-Diverse Persons: A Review. *JAMA Oncol*. 2023 Feb 9. doi: 10.1001/jamaoncol.2022.7173. Online ahead of print.PMID: 36757703
- 89.Antoniotti C, Boccaccino A, Seitz R, Giordano M, Catteau A, Rossini D, Pietrantonio F, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, **Morano F**, Papiani G, Tamburini E, Bensi M, Murgioni S, Ross DT, Passardi A, Boquet I, Nielsen TJ, Galon J, Varga MG, Schweitzer BL, Cremolini C. An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. *Clin Cancer Res*. 2023 Apr 6;CCR-22-3878. doi: 10.1158/1078-0432.CCR-22-3878. Online ahead of print.
- 90.Petrelli A, Rizzolio S, Pietrantonio F, Bellomo SE, Benelli M, De Cecco L, Romagnoli D, Berrino E, Orrù C, Ribisi S, Moya-Rull D, Migliore C, Conticelli D, Maina IM, Puliga E, Serra V, Pellegrino B, Llop-Guevara A, Musolino A, Siena S, Sartore-Bianchi S, Prisciandaro M, **Morano F**, Antista M, Fumagalli U, De Manzoni G, Degiuli M, Baiocchi GL, Amisano MF, Ferraro A, Marchiò C, Corso S, Giordano S. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. *Cancer Res*. 2023 May 2;OF1-OF12. doi: 10.1158/0008-5472.CAN-22-2620. Online ahead of print.
- 91.Leone AG, Miceli R, Trapani D, Massagrande M, **Morano F**, Marsoni S, La Verde N, Berardi R, Casolino R, Lambertini M, Dalu D, Di Maio M, Beretta GD, Perrone F, Cinieri S, Pietrantonio F. Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology. *ESMO Open*. 2023 Jun 2;8(3):101578. doi: 10.1016/j.esmoop.2023.101578. Online ahead of print.
- 92.Boccaccino A, Rossini D, Raimondi A, Carullo M, Lonardi S, **Morano F**, Santini D, Tomasello G, Niger M, Zaniboni A, Daniel F, Bustreo S, Procaccio L, Clavarezza M, Cupini S, Libertini M, Palermo F, Pietrantonio F, Cremolini C. Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. *Eur J Cancer*. 2023 May 6;112910. doi: 10.1016/j.ejca.2023.05.001. Online ahead of print.
- 93.Borelli B, Conca V, Carullo M, Sainato A, Mattioni R, Manfredi B, Balestri R, Bucciante P, Morelli L, Rossi P, Vagli P, Prete AA, Luca F, **Morano F**, Donato SD, Salvatore L, Bengala C, Rossini D, Boni L, Antoniotti C, Cremolini C, Masi G, Moretto R. ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer. *Clin Colorectal Cancer*. 2023 Jun 11;S1533-0028(23)00059-2. doi: 10.1016/j.clcc.2023.06.002.
- 94.Raimondi A, Nichetti F, Stahler A, Wasan HS, Aranda E, Randon G, Kurreck A, Meade AM, Díaz-Rubio E, Niger M, Stintzing S, Palermo F, Trarbach T, Prisciandaro M, Sommerhäuser G, Fisher D, **Morano F**, Pietrantonio F, Modest DP. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. *Eur J Cancer*. 2023 Sep; 190:112945. doi: 10.1016/j.ejca.2023.112945. Epub 2023 Jun 19.

95. Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassinetti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, **Morano F**, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F; GONO Foundation Investigators. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation. *J Clin Oncol*. 2023 Aug 3;JCO2300506. doi: 10.1200/JCO.23.00506. Online ahead of print.
96. Ghelardi F, Raimondi A, **Morano F**, Randon G, Pannone A, Guaglio M, Mazzoli G, Nasca V, Milione M, Leoncini G, Sabella G, Greco GF, Lampis BR, Galassi M, Delfanti S, Nannini M, Intini R, Baratti D, Di Bartolomeo M, Deraco M, Pietrantonio F. Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin. *Clin Colorectal Cancer*. 2023 Aug 11;S1533-0028(23)00078-6. doi: 10.1016/j.clcc.2023.08.005.
97. **Morano F**, Pietrantonio F. Anti-Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer-Another Piece to the Puzzle. *JAMA Netw Open*. 2023 Sep 5;6(9):e2333488. doi: 10.1001/jamanetworkopen.2023.33488.
98. Pretta A, Ziranu P, Giampieri R, Pinna G, Randon G, Donisi C, Ravarino A, Loi F, Deias G, Palmas E, Pretta G, **Morano F**, Semonella F, Mariani S, Deidda MA, Pusceddu V, Puzzone M, Lai E, Solinas C, Restivo A, Zorcolo L, Barbara R, Berardi R, Faa G, Pietrantonio F, Scartozzi M. Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy. *Br J Cancer*. 2023 Sep 25. doi: 10.1038/s41416-023-02444-2. Online ahead of print.
99. Leone AG, Casolino R, Trapani D, Miceli R, Massagrande M, **Morano F**, La Verde N, Dalu D, Berardi R, Marsoni S, Lambertini M, Iula B, Carieri E, Converti M, Di Maio M, Beretta GD, Perrone F, Pietrantonio F, Cinieri S; Italian Foundation of Medical Oncology (Fondazione AIOM); Italian Association of Medical Oncology (AIOM). Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations. *EClinicalMedicine*. 2023 Oct 17;65:102277. doi: 10.1016/j.eclinm.2023.102277. eCollection 2023 Nov.
100. Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, **Morano F**, Pietrantonio F, Seregini E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, Vernieri C. Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2. *J Hematol Oncol*. 2023 Dec 14;16(1):119. doi: 10.1186/s13045-023-01510-9.
101. Nichetti F, Rota S, Ambrosini P, Pircher C, Gusmaroli E, Droz Dit Busset M, Pusceddu S, Sposito C, Coppa J, **Morano F**, Pietrantonio F, Di Bartolomeo M, Mariani L, Mazzaferro V, de Braud F, Niger M. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. *JAMA Netw Open*. 2024 Jan 2;7(1):e2350756. doi: 10.1001/jamanetworkopen.2023.50756
102. Puccini A, Grillo F, Fassan M, Lonardi S, Genuardi M, Cannizzaro R, Cavestro G.M., Marmorino F, Conca V, Salvatore L, Bergamo F, Tosi F, **Morano F**, Daprà V, Molica C, Barana D, Guglielmi A, Signorelli C, D'Amico M, Zoratto F, Iacono D, Morabito A, Martini G, Fabbroncini A, Duro M, Bruera G, Auriemma A, Bonanni B, Percesepe A, Dono M, Battistuzzi L, Labianca R,

- Boni L, Sciallero S and the Lynch Working Group. ItLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients. ESMO Gastrointestinal Oncology, Volume 3, 2024, <https://doi.org/10.1016/j.esmogo.2024.100044>
103. Niger M, Nichetti F, Fornaro L, Pircher C, **Morano F**, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. A phase II/III randomized clinical trial of CisPlatin pLUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patlents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6.
 104. Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Randon G, Kook MC, An JY, Grabsch HI, Prisciandaro M, Nichetti F, Noh SH, Sohn TS, Kim S, Wotherspoon A, **Morano F**, Cunningham D, Lee J, Cheong JH, Smyth EC, Pietrantonio F. Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials. Eur J Cancer. 2024 Apr 4;203:114043. doi: 10.1016/j.ejca.2024.114043. Online ahead of print.
 105. Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, Conca E, Capone I, Busico A, Perrone F, Tamborini E, Sabella G, Greco G, Greco FG, Tafuto S, Procopio G, **Morano F**, Niger M, Maccauro M, Milione M, de Braud F, Pietrantonio F, Pusceddu S. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial. Eur J Cancer. 2024 Sep;209:114276. doi: 10.1016/j.ejca.2024.114276.
 106. Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti O, De Vita F, Bittoni A, Chini C, Spallanzani A, Nappo F, Bethaz V, Strippoli A, Latiano T, Cardellino GG, Giuliani F, **Morano F**, Niger M, Raimondi A, Prisciandaro M, Pircher CC, Sciortino C, Marchesi S, Garattini SK, Airò G, Miceli R, Di Bartolomeo M, Pietrantonio F. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.. Lancet Oncol. 2024 Dec;25(12):1539-1550. doi: 10.1016/S1470-2045(24)00580-1. Epub 2024 Nov 15. PMID: 39557058
 107. Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, Ambrosini P, Fotia G, Hüllelin J, Randon G, Lajer P, Perrone F, Tamborini E, Leoncini G, Coppa J, Busset MDD, Pusceddu S, Milione M, **Morano F**, Pietrantonio F, Pruneri G, Mazzaferro V, Lipka DB, Köhler BC, Hübschmann D, Fröhling S, de Braud F, Niger M. Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer. Cancer Med. 2024 Dec;13(23):e70393. doi: 10.1002/cam4.70393.
 108. Pietrantonio F, **Morano F**, Niger M, Ghelardi F, Chiodoni C, Palazzo M, Nichetti F, Manca P, Cristarella E, Doldi V, Zaffaroni N, Sabella G, Brambilla N, Benincasa E, Giacobelli G, Vitalini C, Girolami F, Rovati LC. The Prostaglandin EP4 Antagonist Vorbipirant Combined with PD-1 Blockade for Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Phase 1b/2a Trial. Clin Cancer Res. 2024 Dec 2;doi: 10.1158/1078-0432.CCR-24-2611. Online ahead of print.
 109. Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, Palermo F, De Manzoni G, Bencivenga M, Bittoni A, Chiodoni C, Lorenzini D, Todoerti K, Manca P, Sangaletti S, Prisciandaro M, Randon G, Nichetti F, Bergamo F, Brich S, Belfiore A, Bertolotti A, Stetco D, Guidi A,

- Torelli T, Vingiani A, Joshi RP, Khoshdeli M, Beaubier N, Stumpe MC, Nappo F, Leone AG, Pircher CC, Leoncini G, Sabella G, Airo' Farulla L, Alessi A, **Morano F**, Martinetti A, Niger M, Fassan M, Di Maio M, Kaneva K, Milione M, Nimeiri H, Sposito C, Agnelli L, Mazzaferro V, Di Bartolomeo M, Pietrantonio F. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. *Ann Oncol*. 2024 Dec 3:S0923-7534(24)04953-6. doi: 10.1016/j.annonc.2024.11.016. Online ahead of print.
110. Trahearn N, Sakr C, Banerjee A, Lee SH, Baker AM, Kocher HM, Angerilli V, **Morano F**, Bergamo F, Maddalena G, Intini R, Cremolini C, Caravagna G, Graham T, Pietrantonio F, Lonardi S, Fassan M, Sottoriva A. Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcome. *J Pathol*. 2025 Feb;265(2):198-210. doi: 10.1002/path.6378.
111. Nasca V, Bergamo F, Foltran L, Antonuzzo L, Bencardino K, Dell'Aquila E, Corallo S, Spallanzani A, Brunetti O, Spada D, Tamberi S, Cella CA, Avallone A, Fornaro L, Di Donato S, Strippoli A, Puccini A, Tamburini E, Palermo F, **Morano F**, Pietrantonio F, Raimondi A. Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial. *BMC Cancer* . 2025 Apr 8;25(1):633. doi: 10.1186/s12885-025-14063-6.

La sottoscritta è a conoscenza che, ai sensi dell'art.76 DPR 28/12/2000 n.445, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, la sottoscritta autorizza al trattamento dei dati personali, secondo quanto previsto dal D. lgs. 196/03.